Compare · NRXS vs SLNO
NRXS vs SLNO
Side-by-side comparison of Neuraxis Inc. (NRXS) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRXS and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 38.4x NRXS ($72.0M).
- Over the past year, NRXS is up 134.0% and SLNO is down 24.3% - NRXS leads by 158.3 points.
- NRXS has hit the wire 13 times in the past 4 weeks while SLNO has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for NRXS).
- Company
- Neuraxis Inc.
- Soleno Therapeutics Inc.
- Price
- $5.71-2.73%
- $53.02+0.08%
- Market cap
- $72.0M
- $2.76B
- 1M return
- -17.19%
- +0.76%
- 1Y return
- +134.02%
- -24.33%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2023
- 2014
- News (4w)
- 13
- 0
- Recent ratings
- 0
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest NRXS
- iAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026
- CMO, SVP Science & Tech Miranda Adrian was granted 199,106 shares (SEC Form 4) to satisfy tax liability
- CRO, CCO, CPO Carrico Thomas Joeseph was granted 193,678 shares, increasing direct ownership by 3,418% to 199,345 units (SEC Form 4) (tax liability)
- Chief Executive Officer Carrico Brian Allen was granted 199,188 shares, increasing direct ownership by 708% to 227,336 units (SEC Form 4) to satisfy withholding obligation
- Neuraxis Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Director Watkins Bradley Mitchell was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)
- SEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian
- Director Keyser Jane Elizabeth was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)
- SEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert
- Director Ferge Kristin A was granted 31,134 shares, increasing direct ownership by 87% to 67,072 units (SEC Form 4)
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)